New marker identifies advanced prostate cancer patients for combo immunotherapy

A new gene expression pattern has emerged as a potential tool for selecting patients with advanced prostate cancer who might respond better to a specific immunotherapy approach. Researchers at The University of Texas MD Anderson Cancer Center identified this signature through a Phase II trial involving men with metastatic castration-resistant prostate cancer (mCRPC) who no longer responded to chemotherapy. The findings, published in Nature Communications, suggest that a subset of these patients could see prolonged survival with a combination of two immune checkpoint inhibitors.

The study evaluated 259 men divided into four treatment groups. Two groups received varying doses of ipilimumab and nivolumab, a pair of drugs designed to boost the immune system’s ability to attack cancer cells. Others got ipilimumab alone or standard chemotherapy. While overall response rates were modest, some patients showed significant tumor shrinkage and drops in prostate-specific antigen levels, a key marker for disease progression.

Dr. Padmanee Sharma, who led the research, emphasized that the findings highlight a gap in current treatment options. “This study reinforces the need to understand how tumors interact with the immune system,” she said. “It’s a step toward personalizing care for patients who have exhausted other therapies.” The team used tissue samples from patients who had exceptional responses to map immune cell activity and gene expression patterns.

The analysis revealed clusters of immune cells in responsive tumors that weren’t present in non-responders. These cells were associated with high activity of specific genes, which the researchers propose could serve as a biomarker. If validated, this signature might help doctors decide whether to pursue immunotherapy or explore alternative treatments before starting care.

However, the trial also noted risks. Nearly a third of patients in the immunotherapy groups experienced serious side effects, including diarrhea, inflammation of the intestines, and issues with the pituitary gland. Two patients died from treatment-related complications, underscoring the need for caution despite the potential benefits.

While the combination therapy isn’t yet approved for this use, the study’s authors argue it could offer hope for a subset of patients. “These results don’t change the overall picture,” Sharma said. “But they show that for some people, this approach might work when other options have failed.”

The research team now plans to test the biomarker in larger trials to confirm its reliability. If successful, the approach could refine treatment strategies for mCRPC, a disease that remains difficult to manage once it becomes resistant to standard therapies. For now, the findings remain preliminary, and the drugs involved are still under investigation.

Patients with chemotherapy-resistant mCRPC often face limited options. The new marker, if validated, could help doctors avoid treatments that may not work for some individuals, potentially sparing them from unnecessary side effects. But the path to approval will require further research to confirm the biomarker’s consistency and the therapy’s long-term impact.

The study’s authors caution against overinterpreting the results. Response rates were low overall, and the trial wasn’t designed to compare different treatment groups directly. Still, the identification of a potential biomarker represents progress in tailoring care for this condition.